http://www.unboundmedicine.com/medline/ebm/research/gemfibrozilUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19919292/full_citation/Validation_of_cell_based_OATP1B1_assays_to_assess_drug_transport_and_the_potential_for_drug_drug_interaction_to_support_regulatory_submissions_Sharma P, Holmes VE, Elsby R, et al. 
Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. [JOURNAL ARTICLE]
Xenobiotica 2009 Nov 17.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19918458/full_citation/Plasmapheresis_in_a_patient_with_rhabdomyolysis:_a_case_report_Swaroop R, Zabaneh R, Parimoo N 
Plasmapheresis in a patient with rhabdomyolysis: a case report. [Journal Article]
Cases J 2009.:8138.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19913963/full_citation/Occurrence_and_fate_of_pharmaceuticals_in_wastewater_treatment_plants_and_rivers_in_Korea_Sim WJ, Lee JW, Oh JE 
Occurrence and fate of pharmaceuticals in wastewater treatment plants and rivers in Korea. [JOURNAL ARTICLE]
Environ Pollut 2009 Nov 12.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19911665/full_citation/[Place_of_fibrates_for_the_treatment_of_patients_with_atherogenic_dyslipidemia]Ducobu J, Scheen AJ, Legat P, et al. 
[Place of fibrates for the treatment of patients with atherogenic dyslipidemia] [English Abstract, Journal Article]
Rev Med Liege 2009 Oct; 64(10):512-8.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19905967/full_citation/Impact_of_chronic_anticholesterol_therapy_on_development_of_microvascular_rarefaction_in_the_metabolic_syndrome_Goodwill AG, Frisbee SJ, Stapleton PA, et al. 
Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome. [Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]
Microcirculation 2009 Nov; 16(8):667-84.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19084089/full_citation/Expert_perspective:_reducing_cardiovascular_risk_in_metabolic_syndrome_and_type_2_diabetes_mellitus_beyond_low_density_lipoprotein_cholesterol_lowering_Jones PH 
Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. [Journal Article]
Am J Cardiol 2008 Dec 22; 102(12A):41L-47L.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19801273/full_citation/Positive_relationship_between_dietary_fat_ethanol_intake_triglycerides_and_hypothalamic_peptides:_counteraction_by_lipid_lowering_drugs_Barson JR, Karatayev O, Chang GQ, et al. 
Positive relationship between dietary fat, ethanol intake, triglycerides, and hypothalamic peptides: counteraction by lipid-lowering drugs. [Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]
Alcohol 2009 Sep; 43(6):433-41.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19779008/full_citation/Using_Complementary_and_Alternative_Medicines_to_Target_the_Host_Response_during_Severe_Influenza_Alleva LM, Cai C, Clark IA 
Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza. [JOURNAL ARTICLE]
Evid Based Complement Alternat Med 2009 Sep 24.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19773540/full_citation/The_Enterohepatic_Disposition_of_Rosuvastatin_in_Pigs_and_The_Impact_of_Concomitant_Dosing_with_Cyclosporine_and_Gemfibrozil_Bergman E, Lundahl A, Fridblom P, et al. 
The Enterohepatic Disposition of Rosuvastatin in Pigs and The Impact of Concomitant Dosing with Cyclosporine and Gemfibrozil. [JOURNAL ARTICLE]
Drug Metab Dispos 2009 Sep 22.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19773535/full_citation/CYP2C8_Activity_Recovers_Within_96_Hours_After_Gemfibrozil_Dosing:_Estimation_of_CYP2C8_Half_life_Using_Repaglinide_as_an_In_Vivo_Probe_Backman JT, Honkalammi J, Neuvonen M, et al. 
CYP2C8 Activity Recovers Within 96 Hours After Gemfibrozil Dosing: Estimation of CYP2C8 Half-life Using Repaglinide as an In Vivo Probe. [JOURNAL ARTICLE]
Drug Metab Dispos 2009 Sep 22.
Abstract | Full Citation